Connection

MICHAEL MANCINI to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications MICHAEL MANCINI has written about Xenograft Model Antitumor Assays.
  1. Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells. Sci Rep. 2021 05 17; 11(1):10461.
    View in: PubMed
    Score: 0.025
  2. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017 04 13; 544(7649):250-254.
    View in: PubMed
    Score: 0.019
  3. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Horm Cancer. 2016 06; 7(3):196-210.
    View in: PubMed
    Score: 0.018
  4. Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death. Cancer Cell. 2015 Aug 10; 28(2):240-52.
    View in: PubMed
    Score: 0.017
  5. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res. 2010 Jan 15; 70(2):842-51.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.